Corporate ActionJul 31, 2026, 09:18 AM
NewcelX Secures $1.4M Equity Financing at 20% Premium
AI Summary
NewcelX Ltd. announced it has secured $1.4 million in equity financing through a private placement. The shares were priced at $4.033 per share, representing a 20% premium to the last closing price, reflecting strong investor confidence. The proceeds will primarily be used to advance NCEL-101, the company's lead program for type 1 diabetes, following a successful FDA Pre-IND meeting, as well as for working capital and general corporate purposes.
Key Highlights
- NewcelX secured $1.4 million in equity financing through a private placement.
- The shares were priced at $4.033 per share, a 20% premium to the last closing price.
- The company is selling 347,134 common shares and warrants to purchase 347,134 common shares.
- Warrants have an exercise price of $4.437 per share, 132% of the last closing price.
- The offering includes participation from existing shareholders and new long-term investors.
- Proceeds will advance NCEL-101, the lead type 1 diabetes program, and for general corporate purposes.
- The financing is expected to close on or about August 14, 2026.
Price Impact
More from NCEL